Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 3Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Neoplasm, Residual 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Burkitt Lymphoma 2Stomach Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Meningeal Carcinomatosis 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphoid 1Leukemia 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

venetoclax 26ibrutinib 23Rituximab 22Cyclophosphamide 21obinutuzumab 18acalabrutinib 18fludarabine phosphate 13fludarabine 13zanubrutinib 8Bendamustine Hydrochloride 8pirtobrutinib 7Biopsy 7Specimen Handling 6Lenalidomide 6CT-P10 6Whole-Body Irradiation 5Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4duvelisib 3Melphalan 3Chlorambucil 3Busulfan 3idelalisib 2daratumumab 2Vincristine 2Prednisone 2Patient Reported Outcome Measures 2Observation 2Mesna 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Lymphocytic, Chronic, B-Cell × Immunotherapy, Adoptive × Clear all
NCT03277729 2026-01-05

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Fred Hutchinson Cancer Center

Phase 1/2 Active not recruiting
53 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04007029 2025-09-05

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
24 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡